Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib

Blood Cancer Journal

Volumn 5, Issue , 2015, Pages

  Atrash, S ^a   Tullos, A ^a   Panozzo, S ^a   Bhutani, M ^b   Van Rhee, F ^a   Barlogie, B ^a   Usmani, S Z ^b  

^a Myeloma Institute for Research and Therapy   (United States)

^b LEVINE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARFILZOMIB; DEXAMETHASONE; OLIGOPEPTIDE;

ADULT; AGED; CANCER PATIENT; CANCER RECURRENCE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DRUG INDUCED DISEASE; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; HEART ARREST; HEART ARRHYTHMIA; HEART FUNCTION; HUMAN; HYPERTENSIVE CRISIS; HYPOTENSION; LETTER; LUNG EDEMA; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; RETROSPECTIVE STUDY; ADVERSE DRUG REACTION; CHEMICALLY INDUCED; HEART DISEASE; PATHOLOGY; TUMOR RECURRENCE;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEART DISEASES; HUMANS; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; OLIGOPEPTIDES;

EID: 84923008413     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.93     Document Type: Letter

References (15)

1. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007; 67: 6383-6391.
2. Yang J, Wang Z, Fang Y, Jiang J, Zhao F, Wong H et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos 2011; 39: 1873-1882.
3. Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, Lorens JB et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009; 114: 3439-3447.
4. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120: 2817-2825.
5. Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012; 119: 5661-5670.
6. Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E et al. Phase 2 doseexpansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 2013; 122: 3122-3128.
7. Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013; 98: 1753-1761.
8. Kyprolis [prescribing information]. South San Francisco; CA: Onyx Pharmaceuticals Inc, 2012.
9. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2108-2121.
10. Honton B, Despas F, Dumonteil N, Rouvellat C, Roussel M, Carrie D et al. Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database. Fundam Clin Pharmacol 2014; 28: 349-352.
11. Enrico O, Gabriele B, Nadia C, Sara G, Daniele V, Giulia C et al. Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol 2007; 138: 396-397.
12. Willis MS, Patterson C. Into the heart: the emerging role of the ubiquitinproteasome system. J Mol Cell Cardiol 2006; 41: 567-579.
13. Li YF, Wang X. The role of the proteasome in heart disease. Biochim Biophys Acta 2011; 1809: 141-149.
14. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Baltimore, MD, USA, 2013. Available at http://www.r-project.org/.
15. Ludwig H, Masszi T, Petrucci MT, Palumbo A, Rosinõl L, Nagler A et al. Carfilzomib (K) vs low-dose corticosteroids and optional cyclophosphamide (CY) in patients (pts) with relapsed and refractory multiple myeloma (RRMM): results from a phase 3 study (FOCUS). Ann Oncol 2014; 25(Suppl 5): v1 (abstract LBA28).